<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Theocharides A</dc:creator>
  <dc:creator>Boissinot M</dc:creator>
  <dc:creator>Girodon F</dc:creator>
  <dc:creator>Garand R</dc:creator>
  <dc:creator>Teo SS</dc:creator>
  <dc:creator>Lippert E</dc:creator>
  <dc:creator>Talmant P</dc:creator>
  <dc:creator>Tichelli A</dc:creator>
  <dc:creator>Hermouet S</dc:creator>
  <dc:creator>Skoda RC</dc:creator>
  <dc:date>2007</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid leukemia (AML). At MPD diagnosis, JAK2-V617F was detectable in 17 of 27 patients. Surprisingly, only 5 of 17 patients developed JAK2-V617F-positive AML, whereas 9 of 17 patients transformed to JAK2-V617F-negative AML. Microsatellite analysis in a female patient showed that mitotic recombination was not responsible for the transition from JAK2-V617F-positive MPD to JAK2-V617F-negative AML, and clonality determined by the MPP1 polymorphism demonstrated that the granulocytes and leukemic blasts inactivated the same parental X chromosome. In a second patient positive for JAK2-V617F at transformation, but with JAK2-V617F-negative leukemic blasts, we found del(11q) in all cells examined, suggesting a common clonal origin of MPD and AML. We conclude that JAK2-V617F-positive MPD frequently yields JAK2-V617F-negative AML, and transformation of a common JAK2-V617F-negative ancestor represents a possible mechanism.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/11148</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1182/blood-2006-12-062125</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/17363731</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Blood. - 2007</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Aged</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Cell Cycle Proteins</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Cell Transformation, Neoplastic</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Chromosome Deletion</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Chromosomes, Human, Pair 11</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Chromosomes, Human, X</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Clone Cells</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Janus Kinase 2</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Kinesin</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Leukemia, Myeloid</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Middle Aged</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Mutation</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Myeloproliferative Disorders</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Phosphoproteins</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Polymorphism, Genetic</dc:subject>
  <dc:title xmlns:ns19="xml" ns19:lang="en">Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
